XBiotech
XBIT
61 hedge funds and large institutions have $46.8M invested in XBiotech in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 16 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
1.66% less ownership
Funds ownership: 15.49% → 13.84% (-1.7%)
8% less funds holding
Funds holding: 66 → 61 (-5)
17% less capital invested
Capital invested by funds: $56.7M → $46.8M (-$9.86M)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
65% less call options, than puts
Call options by funds: $233K | Put options by funds: $674K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$868K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$727K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$315K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$269K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$4.56M |
| 2 |
BlackRock
New York
|
-$2.19M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.43M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$619K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$524K |
XBIT Hedge Fund Activity: Q4 2021 in Review
61 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2021, worth a combined $46.8M — down 17% from $56.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of XBIT and 11 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 22 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $868K. The largest seller was Oracle Investment Management, exiting entirely with an estimated $4.56M sold.
- 61 institutional investors held XBiotech (XBIT) as of Q4 2021, down from 66 in Q3 2021.
- Funds reported $46.8M of XBiotech stock for Q4 2021, down 17% quarter-over-quarter.
- 11 funds opened new XBiotech positions in Q4 2021 and 16 closed out, a net change of -5 holders.
- The largest XBiotech buyer in Q4 2021 was Dimensional Fund Advisors, an estimated $868K added.
- The largest XBiotech seller in Q4 2021 was Oracle Investment Management, an estimated $4.56M sold.
Based on aggregated 13F filings for Q4 2021.